Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Elevated levels of preoperative CA 15-3 and CEA serum levels have independently poor prognostic significance in breast cancer.

Lee JS, Park S, Park JM, Cho JH, Kim SI, Park BW.

Ann Oncol. 2013 May;24(5):1225-31. doi: 10.1093/annonc/mds604. Epub 2012 Dec 9.

2.

Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes.

Park BW, Oh JW, Kim JH, Park SH, Kim KS, Kim JH, Lee KS.

Ann Oncol. 2008 Apr;19(4):675-81. Epub 2007 Nov 23.

3.

Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.

Samy N, Ragab HM, El Maksoud NA, Shaalan M.

Cancer Biomark. 2010;6(2):63-72. doi: 10.3233/CBM-2009-0119.

PMID:
20571232
4.

Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.

Shao Y, Sun X, He Y, Liu C, Liu H.

PLoS One. 2015 Jul 24;10(7):e0133830. doi: 10.1371/journal.pone.0133830. eCollection 2015.

5.

Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers.

Lee JS, Park S, Park JM, Cho JH, Kim SI, Park BW.

Breast Cancer Res Treat. 2013 Oct;141(3):477-84. doi: 10.1007/s10549-013-2695-7. Epub 2013 Sep 27.

PMID:
24072270
6.

[Clinical and prognostic significance of preoperative serum CA153, CEA and TPS levels in patients with primary breast cancer].

Chen Y, Zheng YH, Lin YY, Hu MH, Chen YS.

Zhonghua Zhong Liu Za Zhi. 2011 Nov;33(11):842-6. Chinese.

PMID:
22335950
7.

Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer.

Wu SG, He ZY, Zhou J, Sun JY, Li FY, Lin Q, Guo L, Lin HX.

Breast. 2014 Feb;23(1):88-93. doi: 10.1016/j.breast.2013.11.003. Epub 2013 Dec 2.

PMID:
24291374
8.

Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer.

Uehara M, Kinoshita T, Hojo T, Akashi-Tanaka S, Iwamoto E, Fukutomi T.

Int J Clin Oncol. 2008 Oct;13(5):447-51. doi: 10.1007/s10147-008-0773-3. Epub 2008 Oct 23.

PMID:
18946756
9.

Tumour markers CEA and CA 15-3 as Prognostic factors in breast cancer--univariate and multivariate analysis.

Ebeling FC, Schmitt UM, Untch M, Nagel D, Fateh-Moghadam A, Stieber P, Seidel D.

Anticancer Res. 1999 Jul-Aug;19(4A):2545-50.

PMID:
10470192
10.

Elevated serum CA15-3 levels correlate with positive estrogen receptor and initial favorable outcome in patients who died from recurrent breast cancer.

Nishimura R, Nagao K, Miyayama H, Matsuda M, Baba K, Matsuoka Y, Yamashita H.

Breast Cancer. 2003;10(3):220-7.

PMID:
12955034
11.

Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.

Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Lamerz R.

Anticancer Res. 2000 Nov-Dec;20(6D):5195-8.

PMID:
11326694
12.

The importance of preoperative elevated serum levels of CEA and CA15-3 in patients with breast cancer in predicting its histological type.

Agrawal AK, Jelen M, Rudnicki J, Grzebieniak Z, Zyśko D, Kielan W, Słonina J, Marek G.

Folia Histochem Cytobiol. 2010 Jan 1;48(1):26-9. doi: 10.2478/v10042-010-0030-2.

13.

Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis.

Cañizares F, Sola J, Pérez M, Tovar I, De Las Heras M, Salinas J, Peñafiel R, Martínez P.

Tumour Biol. 2001 Sep-Oct;22(5):273-81.

PMID:
11553856
14.

c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value.

Molina R, Jo J, Filella X, Zanon G, Pahisa J, Mu noz M, Farrus B, Latre ML, Escriche C, Estape J, Ballesta AM.

Breast Cancer Res Treat. 1998 Sep;51(2):109-19.

PMID:
9879773
15.

Use of CA15-3, CEA and prolactin for the primary diagnosis of breast cancer and correlation with the prognostic factors at the time of initial diagnosis.

Arslan N, Serdar M, Deveci S, Ozturk B, Narin Y, Ilgan S, Ozturk E, Ozguven MA.

Ann Nucl Med. 2000 Oct;14(5):395-9.

PMID:
11108173
16.

HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.

Zeiwar MM, Zaki SM, Mohammad LA, Zidan AA, El Nagar MR.

Egypt J Immunol. 2007;14(2):29-41.

PMID:
20306655
17.

Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value.

Molina R, Augé JM, Escudero JM, Filella X, Zanon G, Pahisa J, Farrus B, Muñoz M, Velasco M.

Tumour Biol. 2010 Jun;31(3):171-80. doi: 10.1007/s13277-010-0025-9. Epub 2010 Apr 2.

PMID:
20361287
18.
19.

Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer.

Molina R, Filella X, Alicarte J, Zanon G, Pahisa J, Munoz M, Farrus B, Ballesta AM.

Anticancer Res. 2003 Mar-Apr;23(2A):1035-41.

PMID:
12820344
20.

[Preoperative serum CA15.3 and CEA levels and clinical-biological parameters in breast tumors].

Ruibal A, Garrido Pumar M, Arias JI.

Rev Esp Med Nucl. 2006 May-Jun;25(3):180-3. Spanish.

Items per page

Supplemental Content

Write to the Help Desk